HILDEN, Germany and GERMANTOWN, Maryland, May 25, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
"We are pleased to partner with Therawis, which developed the PITX2 assay and achieved initial clinical validation," said Kai te Kaat, Head of QIAGEN's Oncology Franchise. "The test addresses high unmet needs in breast cancer, the most common malignancy among women, and will add to our expanding portfolio that covers a range of Sample to Insight solutions to further advance personalized healthcare in this and other cancer indications."
Prof. Dr. med. Olaf G. Wilhelm, co-founder and Chief Executive Officer of Therawis, an oncology-focused company founded by clinicians and scientists at the Technical University of Munich commented: "Partnering with QIAGEN will make our PITX2 test widely available in standardized workflows for routine diagnostics and to benefit breast cancer patients globally. We look forward to co-developing and commercializing additional tests. Therawis is uniquely focused on bringing to market predictive diagnostics to guide the optimal therapy for breast cancer patients."
Click here for full press release
John Gilardi Vice President, Corporate Communications and Investor Relations +49-2103-29-11711 Email: firstname.lastname@example.org ir.qiagen.com
SOURCE QIAGEN N.V.